CRL Stock Recent News
CRL LATEST HEADLINES
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution.
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the U.S. Food and Drug Administration (FDA). The company plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, incorporating feedback from the Complete Response Letter (CRL) issued by FDA in July 2024. If the FDA sets a.
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
New Biological Data Released from IRO® Cell Therapy Manufacturing Platform New Biological Data Released from IRO® Cell Therapy Manufacturing Platform
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?